Document is current

Article History

Accepted: 8 December 2022

First Online: 6 February 2023

Declarations

:

: The open access fee for publication of this article was funded by Servier, France.

: The authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. The authors played equal roles in the initial discussions and contributions to the paper and reviewed the successive drafts.

: CN has received consulting fees/honoraria from Amgen, AstraZeneca, Baxter, Bristol Myers Squibb (BMS), Fresenius Kabi, Incyte Biosciences, Merck, MSD, Mylan, Novartis, Nutricia, Pierre Fabre, Roche, Sanofi, and Servier; research funding from Roche and AstraZeneca; and clinical trial funding from OSE Immunotherapeutics, AstraZeneca, BMS, Fresenius Kabi, and Nutricia. PA has received consulting fees from Amgen, AstraZeneca, Baxter, Bayer, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, and Viatris; honoraria for lectures from Amgen, Bayer, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, and Viatris; and travel expenses from Amgen, Pierre Fabre Oncologie, Roche, and Servier. EA: None disclosed. JE has received consulting fees from MSD, Eisai, BMS, AstraZeneca, Bayer, Roche, Ipsen, Basilea, Merck Serono, Incyte, Servier, and Beigene; travel expenses from Amgen; and research funding (institutional) from BMS and Beigene. XA has received fees from Bayer, Ipsen, Eisai, Gilead, and Servier; and travel expenses from Gilead, Viatris, and Ipsen. JCS has received consulting fees from BMS, Servier, Merck Serono, Pierre Fabre Oncologie, Astellas, Incyte and AstraZeneca; and honoraria for lectures from Amgen, Bayer, BMS, MSD, and AstraZeneca. AT has received consulting fees from Servier, Merck Serono, Pierre Fabre Oncologie, and Viatris; and travel expenses from Merck Serono, Sanofi, and AstraZeneca. RC: None disclosed. DM has received consulting fees/honoraria from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Foundation Medicine, Incyte, Leo Pharma, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Taiho, and Viatris; and travel expenses from Amgen, Bayer, BMS, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, and Viatris.

: This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by the authors.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.